David Vicente Baz

机构：Hospital Universitario Virgen Macarena · ORCID：0000-0002-6832-9705

发表论文 58 篇 · 总被引 1491 次 · h-index 15

代表论文

• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study (2024 · Journal of Clinical Oncology · 被引 211)
• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 154)
• Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study (2024 · Journal of Clinical Oncology · 被引 126)
• LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 (2023 · Annals of Oncology · 被引 56)
• LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen (2022 · Annals of Oncology · 被引 21)
• Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study (2023 · Journal of Thoracic Oncology · 被引 19)